TSE:4568Pharmaceuticals
Assessing Daiichi Sankyo (TSE:4568) Valuation After A Flurry Of New Drug Development Partnerships
Daiichi Sankyo Company (TSE:4568) has attracted fresh attention after a cluster of partnerships with Interna Therapeutics, Wayfinder Biosciences, and 4D Path tied to drug delivery, RNA targeting, and AI supported biomarker development.
See our latest analysis for Daiichi Sankyo Company.
These research alliances and the recent U.S. FDA Priority Review for ifinatamab deruxtecan arrive while the 1 day share price return of 1.73% and 7 day share price return of 6.01% contrast with a weaker year...